财务业绩 - 公司Q1营收为79.15亿美元，调整后营收为80.04亿美元，同比增长2.8%，有机增长5.3%[9] - 公司Q1GAAP每股收益为0.80美元，非GAAP每股收益为1.23美元，分别同比增长36%和3%[10] - 公司第一季度总收入为79.15亿美元，同比增长2.8%[52] - 营业利润12.78亿美元，同比增长0.8%[52] - 净利润10.42亿美元，同比增长31.7%[52] - 每股摊薄收益0.80美元，同比增长35.6%[52] - 公司本季度非GAAP调整后的毛利率为65.9%，较上年同期提升0.8个百分点[55] - 公司本季度非GAAP调整后的营业利润率为24.4%，较上年同期提升5.3个百分点[55] - 公司本季度非GAAP调整后的每股摊薄收益为1.23美元，较上年同期增长7.9%[55] - 公司本季度非GAAP调整后的有效税率为17.0%，较上年同期下降0.4个百分点[55] 业务表现 - 心血管业务收入30.07亿美元，同比增长5.5%，有机增长6.9%[12,13,14,15,16] - 神经科学业务收入23.17亿美元，同比增长4.4%，有机增长5.3%[17,18,19,20,21] - 糖尿病业务收入6.47亿美元，同比增长11.8%，有机增长12.6%[24,25,26,27] - 心血管业务收入28.50亿美元，同比增长5.5%[43] - 神经科学业务收入22.19亿美元，同比增长4.4%[43] - 医疗外科业务收入20.05亿美元，同比下降0.4%[43] - 糖尿病业务收入5.78亿美元，同比增长11.8%[43] - 美国市场收入40.82亿美元，同比增长4.0%[46] - 国际市场收入38.32亿美元，同比增长1.5%[49] 现金流与资产负债 - 公司本季度经营活动产生的现金流量为9.86亿美元，较上年同期增长12.7%[65] - 公司本季度资本支出为5.20亿美元，较上年同期增长47.2%[65] - 公司本季度自由现金流为4.66亿美元，较上年同期下降10.6%[65] - 公司本季度现金及现金等价物余额为13.11亿美元，较上年度末增长2.1%[68] - 公司本季度总资产为897.49亿美元，较上年度末下降0.3%[68] - 公司本季度新增长期债务32.09亿美元[71] - 公司本季度回购普通股24.92亿美元[71] - 公司本季度支付股利8.98亿美元[71] - 公司本季度资本支出为5.20亿美元，同比增长46.9%[71] - 公司本季度购买投资17.79亿美元，同比减少1.9%[71] - 公司本季度销售和到期投资21.57亿美元，同比增长23.4%[71] 业务展望 - 公司提高了2025财年有机收入增长和每股收益指引[28,29,30,31] - 公司本季度研发投入为6.62亿美元，占收入的6.3%[71] - 公司本季度股票激励费用为8300万美元，同比增长13.7%[71]

Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pain Stimulation, and Deep Brain StimulationGALWAY, Ireland, Aug. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024.Key HighlightsRevenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as repo ...

Medtronic plc (MDT) is scheduled to report first-quarter fiscal 2025 results on Aug 20, before the opening bell.In the last reported quarter, the company’s adjusted earnings of $1.46 exceeded the Zacks Consensus Estimate by 0.69%. Medtronic beat estimates in each of the trailing four quarters, the average surprise being 4.48%.The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $7.90 billion, suggesting growth of 2.5% year over year. The consensus estimate for first-quarter earnings i ...

JHVEPhoto Medtronic (NYSE:MDT) continues to tread water as the broader market advances. The stock is up just 4% over the past 12 months, significantly underperforming the iShares U.S. Medical Devices ETF (IHI) which is higher by 10%. The Health Care Sector ETF (XLV) has returned better than 15% while the S&P 500 has beaten them all with a 28% performance from year-ago levels. I reiterate a buy rating on MDT, though. I see the stock as still undervalued today ahead of its Q1 2025 earnings report due out ...

JHVEPhotoInvestment thesis My initial bullish thesis about Medtronic (NYSE:MDT) aged somewhat good as the stock delivered a total 1.9% return since mid-February. As I underlined in my initial thesis, MDT is a good option for investors seeking low-volatility stock with solid dividend growth. The company reports its fiscal Q1 earnings soon, on August 20. Today I want to update my thesis and explain why I believe there are robust reasons to remain moderately bullish about MDT. Moreover, the valuation still ...

The office building of Medtronic Inc., an American medical technology company, is being pictured in ... [+] Shanghai, China, on July 23, 2024. (Photo by Costfoto/NurPhoto via Getty Images)NurPhoto via Getty ImagesMedtronic (NYSE: MDT) is scheduled to report its fiscal 2025 first-quarter results on Tuesday, August 20 (fiscal year ends in April). We expect Medtronic stock to trade higher post-Q1 results announcement, with its revenues and earnings expected to be slightly above the street estimates. The compan ...

GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividen ...

Medtronic (MDT) recently announced two major developments within its diabetes care business. The company received FDA approval for its Simplera continuous glucose monitor (CGM), which marks a significant step forward in diabetes management.Along with the FDA approval, Medtronic announced a global partnership with another MedTech stalwart, Abbott (ABT) . Considering the fact that the global diabetes care market has shown remarkable growth over the past few years, this partnership is expected to be strategica ...

In its upcoming report, Medtronic (MDT) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $7.9 billion, representing a year-over-year increase of 2.5%.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Before a company reveals its earni ...

ab 14 August 2024 Global Research and Evidence Lab Medtronic PLC Diabetes Turnaround Sustainable, Clearing Path to MSD Sales Growth; U/G to Neutral CGM Partnership Potentially Transformative for MDT Diabetes We are upgrading MDT to Neutral from Sell as we now have higher conviction that the recent Diabetes turnaround is sustainable. With Diabetes representing just under 10% of MDT's sales but also one of MDT's higher growth end markets, this business is critical to MDT's top-line growth trajectory. With thi ...